Larimar Therapeutics, Inc. Balance Sheet
LRMR|6 years of annual SEC 10-K data (FY2014-FY2019)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
Larimar Therapeutics, Inc. had $81M in total assets and $93M in shareholders' equity as of FY2019.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.2M | $49.3M | $35.6M | $58.1M | $35.5M | $9.9M |
| Current Assets | $71.5M | $121.3M | $104.9M | $130.9M | $188.1M | $117.2M |
| PP&E (Net) | $821.0K | $375.0K | $528.0K | $661.0K | $902.0K | $79.0K |
| Total Assets | $80.7M | $121.8M | $105.5M | $131.6M | $189.1M | $117.5M |
| Current Liabilities | $12.2M | $13.3M | $7.3M | $9.9M | $16.5M | $6.9M |
| Total Debt | - | - | $20.0M | - | - | - |
| Shareholders' Equity | $93.3M | $121.7M | $169.1M | $104.4M | -$68.6M | -$54.7M |